Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33. Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with...
Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue...
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and...
Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual meetingHan Choi, M.D., LL.M, seasoned healthcare institutional investor, appointed...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.509 | 59.8119858989 | 0.851 | 1.62 | 0.8192 | 1883150 | 1.22286373 | CS |
4 | 0.51 | 60 | 0.85 | 1.62 | 0.8 | 898085 | 1.07999337 | CS |
12 | 0.68 | 100 | 0.68 | 1.62 | 0.6354 | 632204 | 0.92975289 | CS |
26 | 0.33 | 32.0388349515 | 1.03 | 1.62 | 0.6354 | 704183 | 0.9130393 | CS |
52 | -0.89 | -39.5555555556 | 2.25 | 3.1399 | 0.6354 | 516824 | 1.18450615 | CS |
156 | -10.31 | -88.3461868038 | 11.67 | 12.73 | 0.6354 | 261925 | 2.43875258 | CS |
260 | -40.66 | -96.7634459781 | 42.02 | 63.62 | 0.6354 | 239871 | 6.29085048 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.